Skip to content

Archive for January 2019

CHAMP Calls for CGRP Coverage in the UK

Respect Migrane Disease Cover CGRP Medicines

The UK’s National Institute for Health and Care Excellence (NICE) recently released draft guidance indicating that they will not approve Aimovig (erenumab) for coverage through the country’s National Health Service. While those prescribed Aimovig, a CGRP inhibitor produced by Novartis/Amgen, may pay out-of-pocket to receive the treatment, the cost of the medicine will keep many…

Read More
Scroll To Top